Le Lézard
Classified in: Health
Subjects: TDS, FVT

Neosanté Health Solutions is attending ECRM® EPPS event in Phoenix, Arizona


BOCA RATON, Fla., Sept. 18, 2018 /PRNewswire/ -- Neosanté Health Solutions, creators of Delictase Oral Drops, is attending September's ECRM® EPPS event in Phoenix, Arizona to showcase its unique lactase enzyme to treat baby colic.

About 40 percent of children suffer from baby colic when they are between six weeks and six months.

The Vitamin, Weight Management and Sports Nutrition Efficient Program Planning Sessions (EPPS) is a trade show where vitamin and nutrition companies, like Neosanté, will have the opportunity to, represented by Brian Gould and Jeff Fernandez, network with major retail buyers in private sessions to present their products. The event will take place at the Pointe Hilton Tapatio Cliffs Resort in Phoenix from Sept. 30 to Oct. 4.

"Attending ECRM is an exciting opportunity that we could not pass," João Santos, Neosanté's CEO, said. "We are confident this event will be successful and that buyers will notice the uniqueness of Delictase oral drops."

About 40 percent of children suffer from baby colic when they are between six weeks and six months. Fortunately, Delictase oral drops prevent the excessive crying and discomfort sometimes felt by babies suffering from the condition.

EPPS is a branch of the Efficient Collaborative Retail Marketing (ECRM®) event series where brands are able to have direct discussions with retailers and other brands about business objectives like product launches, marketing campaigns and more. Some of the major retailers include Amazon.com, Costco, CVS, GNC, Harris Teeter, LuckyVitamin.com, Meijer, Sam's Club, The Fresh Market, Vitamin Shoppe, Walgreens, Whole Foods and more.

Some of the symptoms that may contribute to baby colic include lactose intolerance, food allergy, intestinal microflora disorders, incorrect feeding technique and psychological factors. Lactose is the main carbohydrate found in breast milk and infant formulas. For this reason, it is important to treat transient lactose intolerance to allow babies to receive the necessary glucose and galactose intake they need in order for their bodies to function and develop properly.

For more information on Delictase Oral Drops®, now available on amazon, visit www.delictase.com.

Please direct inquiries to:
Michelle Bizet, 561-544-0719
[email protected]

SOURCE Neosanté Health Solutions


These press releases may also interest you

at 05:12
Sobi establishes MTN programme with a framework amount of SEK 10 billion, publishes a base prospectus
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...

at 04:00
OMRON Donates Some 3,200 Units of Blood Pressure Monitors to Global Blood Pressure Screening Campaign on World Hypertension Day
OMRON Healthcare Co., Ltd. based in Muko, Kyoto Prefecture, Japan, announces to be the official sponsor of May Measurement Month (MMM,) a global campaign to raise awareness of blood pressure screening and promote hypertension prevention, detection,...

at 02:48
RaySearch publishes Annual Report for 2023
Today, RaySearch Laboratories AB (publ)  publishes its Annual Report for the financial year 2023. The report is held available on RaySearch's website, under the section Investors.  This information is information that RaySearch Larboratiories AB...

at 02:43
ZINZINO AB (PUBL): NOTICE OF ANNUAL GENERAL MEETING IN ZINZINO AB ON MAY 27, 2024
Shareholders of Zinzino AB (publ) are hereby invited to the annual general meeting on Monday, May 27, 2024, at 1:30 PM at the company's premises at Hulda Mellgrens gata 5 in Gothenburg. Registration begins at 1:15 PM. The company aims to webcast the...

at 02:41
Implantica publishes Annual Report 2023
Implantica AG (publ), a med-tech company at the forefront of bringing advanced technology into the body, is publishing its annual report for the fiscal year 2023. The annual report is now available on the company's website. "Implantica had a very...

at 02:08
Interim report January-March 2024: Medicover
Revenue amounted to ?498.8m (?419.3m), an increase of 18.9% with an organic growth of 14.2%.Operating profit (EBIT) was ?19.0m (?10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%).Net profit amounted to ?6.5m (?2.1m), which...

More news about Health...


News published on and distributed by: